PTAB: Roche patent can’t evade IPR under Fintiv

Roche unit Chugai failed to persuade the US Patent Trial and Appeal Board (PTAB) that it should not institute inter partes reviews (IPRs) of a patent covering Actemra (Atlizumab), a treatment for arthritis under the NHK/Fintiv rule.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

English court says Roche did not infringe insulin pump patents

13 July 2021 The English High Court has cleared Roche of patent infringement claims over its line of insulin pumps but shot down the pharma giant’s attempt to invalidate the plaintiff’s patent.

Big Pharma

Amgen asks SCOTUS to reject Roche petition

14 April 2021 Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

More on this story

Medtech

English court says Roche did not infringe insulin pump patents

13 July 2021 The English High Court has cleared Roche of patent infringement claims over its line of insulin pumps but shot down the pharma giant’s attempt to invalidate the plaintiff’s patent.

Big Pharma

Amgen asks SCOTUS to reject Roche petition

14 April 2021 Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

More on this story

Medtech

English court says Roche did not infringe insulin pump patents

13 July 2021 The English High Court has cleared Roche of patent infringement claims over its line of insulin pumps but shot down the pharma giant’s attempt to invalidate the plaintiff’s patent.

Big Pharma

Amgen asks SCOTUS to reject Roche petition

14 April 2021 Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages

PTAB: Roche patent can’t evade IPR under Fintiv

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features